Free Trial

Omeros (OMER) Competitors

Omeros logo
$3.36 -0.12 (-3.45%)
Closing price 04:00 PM Eastern
Extended Trading
$3.50 +0.14 (+4.17%)
As of 07:59 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

OMER vs. NKTR, ASMB, CPIX, LLY, JNJ, ABBV, MRK, PFE, BMY, and ZTS

Should you be buying Omeros stock or one of its competitors? The main competitors of Omeros include Nektar Therapeutics (NKTR), Assembly Biosciences (ASMB), Cumberland Pharmaceuticals (CPIX), Eli Lilly and Company (LLY), Johnson & Johnson (JNJ), AbbVie (ABBV), Merck & Co., Inc. (MRK), Pfizer (PFE), Bristol Myers Squibb (BMY), and Zoetis (ZTS). These companies are all part of the "pharmaceuticals" industry.

Omeros vs. Its Competitors

Omeros (NASDAQ:OMER) and Nektar Therapeutics (NASDAQ:NKTR) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their dividends, earnings, analyst recommendations, institutional ownership, valuation, media sentiment, risk and profitability.

Omeros has a beta of 2.16, suggesting that its share price is 116% more volatile than the S&P 500. Comparatively, Nektar Therapeutics has a beta of 0.94, suggesting that its share price is 6% less volatile than the S&P 500.

48.8% of Omeros shares are owned by institutional investors. Comparatively, 75.9% of Nektar Therapeutics shares are owned by institutional investors. 12.9% of Omeros shares are owned by company insiders. Comparatively, 5.3% of Nektar Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Omeros has a net margin of 0.00% compared to Nektar Therapeutics' net margin of -152.49%. Omeros' return on equity of 0.00% beat Nektar Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
OmerosN/A N/A -59.68%
Nektar Therapeutics -152.49%-329.54%-55.24%

Omeros currently has a consensus price target of $18.00, indicating a potential upside of 435.71%. Nektar Therapeutics has a consensus price target of $88.33, indicating a potential upside of 254.18%. Given Omeros' higher possible upside, research analysts plainly believe Omeros is more favorable than Nektar Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omeros
0 Sell rating(s)
2 Hold rating(s)
3 Buy rating(s)
1 Strong Buy rating(s)
2.83
Nektar Therapeutics
0 Sell rating(s)
1 Hold rating(s)
6 Buy rating(s)
0 Strong Buy rating(s)
2.86

In the previous week, Nektar Therapeutics had 3 more articles in the media than Omeros. MarketBeat recorded 8 mentions for Nektar Therapeutics and 5 mentions for Omeros. Omeros' average media sentiment score of 1.12 beat Nektar Therapeutics' score of 0.58 indicating that Omeros is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Omeros
1 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Nektar Therapeutics
2 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Nektar Therapeutics has higher revenue and earnings than Omeros. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Omeros, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
OmerosN/AN/A-$156.82M-$2.65-1.27
Nektar Therapeutics$98.43M3.14-$118.96M-$9.60-2.60

Summary

Omeros beats Nektar Therapeutics on 9 of the 16 factors compared between the two stocks.

Get Omeros News Delivered to You Automatically

Sign up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMER and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OMER vs. The Competition

MetricOmerosMED PRODUCTS IndustryMedical SectorNASDAQ Exchange
Market Cap$203.90M$10.25B$5.54B$9.41B
Dividend YieldN/A2.06%3.75%4.03%
P/E Ratio-1.2716.5828.0119.82
Price / SalesN/A30.02433.8198.96
Price / CashN/A22.3936.1658.27
Price / Book-1.073.578.125.65
Net Income-$156.82M$235.43M$3.25B$257.91M
7 Day Performance-7.95%-1.67%0.97%2.09%
1 Month Performance4.35%2.91%7.36%11.13%
1 Year Performance-31.15%-16.44%31.31%18.40%

Omeros Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OMER
Omeros
3.7837 of 5 stars
$3.36
-3.4%
$18.00
+435.7%
-33.1%$203.90MN/A-1.27210Positive News
Analyst Revision
Gap Up
NKTR
Nektar Therapeutics
4.0618 of 5 stars
$24.41
-2.4%
$88.33
+261.9%
+22.6%$302.86M$87.25M-2.54220Analyst Revision
ASMB
Assembly Biosciences
3.7919 of 5 stars
$18.84
+0.5%
$33.00
+75.2%
+27.1%$143.90M$32.15M-3.02100Trending News
CPIX
Cumberland Pharmaceuticals
0.8866 of 5 stars
$3.40
+13.3%
N/A+152.4%$50.87M$41.08M-13.6080Trending News
LLY
Eli Lilly and Company
4.9798 of 5 stars
$799.51
+0.8%
$1,012.56
+26.6%
-15.8%$757.72B$49.00B65.0547,000Trending News
JNJ
Johnson & Johnson
4.7823 of 5 stars
$156.91
+0.0%
$171.00
+9.0%
+4.1%$377.55B$89.33B17.45138,100Trending News
Earnings Report
Dividend Announcement
Analyst Forecast
Options Volume
Analyst Revision
ABBV
AbbVie
4.7836 of 5 stars
$191.54
-0.5%
$211.29
+10.3%
+9.1%$338.33B$56.33B81.5055,000Trending News
Ex-Dividend
Analyst Revision
MRK
Merck & Co., Inc.
4.9955 of 5 stars
$83.72
+0.4%
$108.69
+29.8%
-35.2%$210.21B$64.17B12.1975,000Positive News
PFE
Pfizer
4.9618 of 5 stars
$25.36
-1.2%
$28.55
+12.6%
-18.1%$144.15B$62.46B18.3781,000Trending News
BMY
Bristol Myers Squibb
4.8944 of 5 stars
$47.36
+1.1%
$57.69
+21.8%
+11.4%$96.38B$47.64B17.7434,100Trending News
Analyst Revision
ZTS
Zoetis
4.9604 of 5 stars
$155.68
+0.5%
$212.13
+36.3%
-17.6%$69.31B$9.26B27.9513,800Trending News
Analyst Downgrade
Analyst Revision

Related Companies and Tools


This page (NASDAQ:OMER) was last updated on 7/18/2025 by MarketBeat.com Staff
From Our Partners